Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DAROLUTAMIDE Cause Prostatic specific antigen increased? 156 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 156 reports of Prostatic specific antigen increased have been filed in association with DAROLUTAMIDE (NUBEQA). This represents 4.8% of all adverse event reports for DAROLUTAMIDE.

156
Reports of Prostatic specific antigen increased with DAROLUTAMIDE
4.8%
of all DAROLUTAMIDE reports
9
Deaths
23
Hospitalizations

How Dangerous Is Prostatic specific antigen increased From DAROLUTAMIDE?

Of the 156 reports, 9 (5.8%) resulted in death, 23 (14.7%) required hospitalization.

Is Prostatic specific antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DAROLUTAMIDE. However, 156 reports have been filed with the FAERS database.

What Other Side Effects Does DAROLUTAMIDE Cause?

Fatigue (384) Death (361) Hot flush (203) Asthenia (173) Off label use (133) Neuropathy peripheral (127) Diarrhoea (122) Dizziness (122) Rash (116) Arthralgia (115)

What Other Drugs Cause Prostatic specific antigen increased?

ENZALUTAMIDE (3,731) LEUPROLIDE (2,432) ABIRATERONE (1,581) RADIUM RA-223 DICHLORIDE (449) RELUGOLIX (335) BICALUTAMIDE (322) DOCETAXEL (282) APALUTAMIDE (251) DENOSUMAB (220) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)

Which DAROLUTAMIDE Alternatives Have Lower Prostatic specific antigen increased Risk?

DAROLUTAMIDE vs DARUNAVIR DAROLUTAMIDE vs DARUNAVIR ETHANOLATE DAROLUTAMIDE vs DARUNAVIR\RITONAVIR DAROLUTAMIDE vs DASABUVIR DAROLUTAMIDE vs DASABUVIR\OMBITASVIR HEMINONAHYDRATE\PARITAPREVIR\RITONAVIR

Related Pages

DAROLUTAMIDE Full Profile All Prostatic specific antigen increased Reports All Drugs Causing Prostatic specific antigen increased DAROLUTAMIDE Demographics